![]()
|
|
||||||||
J Biol Chem, Vol. 275, Issue 2, 721-724, January 14, 2000
,From the Connective Tissue Biology Laboratories, Cardiff School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3US, United Kingdom
| |
ABSTRACT |
|---|
|
|
|---|
This study describes specific molecular
mechanisms by which supplementation with n-3 fatty acids
(i.e. those present in fish oils) can modulate the
expression and activity of degradative and inflammatory factors that
cause cartilage destruction during arthritis. Our data show that
incorporation of n-3 fatty acids (but not other
polyunsaturated or saturated fatty acids) into articular cartilage
chondrocyte membranes results in a dose-dependent reduction
in: (i) the expression and activity of proteoglycan degrading enzymes
(aggrecanases) and (ii) the expression of inflammation-inducible cytokines (interleukin (IL)-1 Noninvasive, pharmaceutical-based therapies for the treatment of
arthritic diseases are primarily limited to oral administration of
nonsteroidal antiinflammatory drugs, which inhibit cyclooxygenase (COX)1-mediated production of
inflammatory eicosanoids such as prostaglandins (1, 2).
Parenthetically, clinical studies on dietary supplementation with
n-3 (omega-3) fatty acids (the principle long chain
polyunsaturated fatty acids found in fish oils) have also demonstrated
modulation of inflammatory symptoms involved in the pathogenesis of
arthritis (3-5). Such epidemiological observations have been largely
anecdotal, because they did not investigate the molecular mechanisms
whereby dietary n-3 fatty acid supplementation might affect
the metabolism of cells within articular joint tissues and thereby
provide relief to arthritic symptoms. Significantly, however, dietary
supplementation with n-3 fatty acids elicits
antiinflammatory effects in neutrophils and monocytes by inhibiting the
5-lipoxygenase pathway responsible for metabolism of arachidonic acid
to leukotrienes (6). Furthermore, n-3 fatty acid
supplementation can also suppress phospholipase C-mediated signal
transduction (7), thus demonstrating additional molecular mechanisms
whereby n-3 fatty acids can specifically affect cell metabolism.
One of the key pathological features common to degenerative joint
diseases (arthritis) is the loss of cartilage proteoglycan (aggrecan),
which precedes subsequent cartilage erosion. Catabolism of aggrecan is
mediated by the proteolytic activity of aggrecanases (8-11), two
isoforms of which have recently been purified and cloned (12, 13).
Aggrecanase activity is up-regulated by cartilage exposure to
pro-inflammatory cytokines such as IL-1 and TNF- To determine a molecular basis for potential therapeutic properties
associated with dietary intake of fish oils, we investigated the
effects of different classes of fatty acids on the expression and
activity of cartilage aggrecanases, cytokines (IL-1 Isolation and Culture of Bovine Chondrocytes--
Bovine
articular cartilage was obtained from the metacarpo- and
metatarsophalangeal joints of 7-day-old calves. Cartilage tissue slices
were dissected under sterile conditions and subjected to standard
Pronase and collagenase digestion to isolate the chondrocytes as
described previously (9). Monolayer cultures were established in 60-mm
diameter culture dishes by plating 1 ml/dish of a suspension of 6 × 106 chondrocytes/ml of DMEM (~2 × 105 cells/cm2). Cultures were maintained for
8 h in the absence or presence (10-100 µg/ml) of
polyunsaturated n-3 fatty acids ( Fatty Acid Analysis of Chondrocyte Membranes--
Chondrocyte
cell layers were harvested using a rubber policeman and washed three
times in phosphate-buffered saline by centrifugation for 10 min at
1000 × g. The cells were resuspended in 1 ml deionized water and sonicated for 30 min in an ultrasonic water bath. Once complete lysis of the cells had been achieved, extraction of the lipids
was performed (24). Briefly, 1 ml of cell lysate was mixed with 3.75 ml
of chloroform/methanol (1:2 v/v) and incubated for 30 min at 20 °C.
Following the addition of 1.25 ml of chloroform and 1.25 ml of Garbus
solution (2 M KCl, 0.5 M KPO4, pH
7.4), the chloroform phase of all mixtures was dried down in a stream of nitrogen. Generation of fatty acid methyl esters was achieved by
addition of H2SO4 (2.5%) in anhydrous methanol
(1%). As an internal standard an appropriate quantity of
pentadecaenoic acid (15:0) was added. After sealing, the tubes were
heated for 2 h at 70 °C. The tubes were then cooled and 2.5 ml
of 5% NaCl was added. The methyl esters were extracted three times
with 3 ml of petroleum ether, dried down in a stream of nitrogen, and
then redissolved in chromatographically pure petroleum ether. The
methyl esters were analyzed using gas chromatography, with the yields of fatty acid being calculated from the known amount of internal standard.
Analyses of Chondrocyte Metabolism and Phenotype--
Cellular
DNA content of all chondrocyte cultures was measured using the Hoechst
33258 dye DNA assay (25). Proteoglycan synthesis was measured by
radiolabeling cultures for 96 h with [35S]sulfuric
acid (20 µCi/ml). Unincorporated radiolabel was removed from the
culture media and cell layer extracts using a Sephadex G-50 column
(Amersham Pharmacia Biotech) and total counts/min in the void volume
measured. The concentration of lactate in culture media was measured
using a commercial lactate assay kit (Sigma-Aldrich Co.). The
expression of mRNAs for two genes which are characteristic of the
chondrocyte phenotype (i.e. aggrecan and collagen type II)
was assessed by RT-PCR as described below.
Western Blot Analyses of Aggrecanase- or Matrix
Metalloproteinase-generated Aggrecan Catabolites--
To detect the
occurrence of aggrecanase or matrix metalloproteinase activity in the
monolayer cultures, portions of conditioned media containing an
equivalent quantity of proteoglycan metabolites (measured by
dimethylmethylene blue assay (26)) were analyzed by SDS-polyacrylamide
gel electrophoresis and Western blotting as described previously (9).
Briefly, after deglycosylation with chondroitinase ABC (Sigma-Aldrich
Co.), keratanase and keratanase II (Seikagaku/AMS Biotechnology,
Abingdon, UK), aggrecan fragments were separated on 4-12% gradient
gels (Novex, Frankfurt, Germany) and electrophoretically transferred to
nitrocellulose. Membranes were then probed using monoclonal antibody
BC-3 (which specifically recognizes the aggrecanase-generated
neoepitope N-terminal sequence 374ARGSV ... on
aggrecan metabolites) or monoclonal antibody BC-14 (which specifically
recognizes the matrix metalloproteinase-generated neoepitope N-terminal
sequence 342FFGVG ... on aggrecan metabolites)
(9).
RNA Extraction and RT-PCR Analyses--
Bovine chondrocyte
monolayer cultures were extracted by direct addition of Tri-Reagent
(Sigma-Aldrich Co.). Following the addition of chloroform (0.2 ml/1 ml
of Tri-Reagent) and centrifugation for 20 min at ~16,000 × g, total RNA from the aqueous phase of all extracts was
isolated using Rneasy mini-columns and reagents (Qiagen, Crawley, Ltd.,
Crawley, UK). Because spectrophotometric analyses revealed a
reasonable, but relatively low, yield of total RNA (approximately 20 µg/60-mm culture dish), we utilized RT-PCR methods to examine
chondrocyte gene transcription. First strand cDNA was synthesized
by reverse transcription and PCR amplification was performed as
described (27) using oligonucleotide primers corresponding to
cDNA sequences for aggrecan (CGCTACGACGCCATCTGCTAC and
GCCTGCTGTGCCTCCTCAAA; GenBankTM accession number M55172),
collagen II- In this study, articular cartilage chondrocytes were exposed in
culture to fatty acids at concentrations which cover the typical range
(50-70 µg/ml) for free fatty acid levels in human plasma (28). The
results for measurements of the lipid content of chondrocytes supplemented without or with a polyunsaturated n-3 (
and tumor necrosis factor (TNF)-
) and cyclooxygenase (COX-2), but not the constitutively expressed cyclooxygenase COX-1. These findings provide evidence that
n-3 fatty acid supplementation can specifically affect
regulatory mechanisms involved in chondrocyte gene transcription and
thus further advocate a beneficial role for dietary fish oil
supplementation in alleviation of several of the physiological
parameters that cause and propogate arthritic disease.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
, and model
cartilage explant and chondrocyte culture systems stimulated with IL-1
or TNF-
mimic the degradative processes involving aggrecan catabolism which occur during arthritis (14-18). In addition, exposure to these inflammatory mediators propogates the autocrine synthesis of
cartilage cytokines, which contribute to the chronic progression of
arthritis. Furthermore, cytokine-induced degradative activities in
synovial joint tissues can be potentiated via the biosynthesis of
inflammatory eicosanoids by the cyclooxygenases COX-1 and COX-2 (1, 2).
COX-1, which is constitutively expressed in most tissues, is
responsible for key aspects of eicosanoid biosynthesis, which are
important in maintaining homeostasis during normal cellular metabolism
(19). Conversely, COX-2 expression and activity is induced during
inflammation, and it is this enzyme that is selectively involved in
inflammatory aspects of arthritic disease (20, 21). Consequently,
modulation of COX-2 activity has been a major target of pharmaceutical
companies for intervention in the pathogenesis of arthritis (22).
and TNF-
) and
cyclooxygenases (COX-1 and COX-2). The results of these in vitro studies reveal that exposure of articular chondrocytes to n-3 fatty acids can specifically modulate, at the level of
gene transcription, key factors involved in articular cartilage degradation.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
18:3
linolenate,2 20:5
eicosapentaenoate or 22:6 docosahexaenoate), a polyunsaturated n-6 fatty acid (18:2 linoleate), a saturated fatty acid
(16:0 palmitate), or a monounsaturated fatty acid (18:1 oleate). All fatty acids were minimum 99% purity from Sigma-Aldrich Co., Poole, United Kingdom. Prior to their addition to culture media, fatty acids
were incubated as described (23) for 16 h at 37 °C in Tyrode-HEPES buffer (20 mM HEPES, 140 mM NaCl,
4.5 mM KCl, 1 mM MgCl2, 2.5 mM CaCl2, 11 mM glucose, pH 7.4)
containing 3.5 mg/ml fatty acid-free bovine albumin (Fraction V,
Sigma-Aldrich Co.) at a ratio of 3:1 fatty acid:albumin. The culture
medium was removed and then replaced with fresh medium (without fatty
acid) supplemented with or without 10 ng/ml IL-1
.
I (TGCCTGGTGCTCCTGGTCTGA and CTTCTCCCTTCTCGCCGTTAG;
GenBankTM accession number X16711), aggrecanase-1
(ACCACTTTGACACAGCCATTC and ACCCCCACAGGTCCGAGAGCA; GenBankTM
accession number AF148213), aggrecanase-2 (TGTGCTGTGATTGAAGACGAT and
GACTGCAGGAGCGGTAGATGG; GenBankTM accession number
AF142099), COX-1 (GCCCAACACTTCACCCATCAG and CCAGGAAGCAGCCCAAACACT;
GenBankTM accession number AF004943), COX-2
(GCTCTTCCTCCTGTGCCTGAT and CATGGTTCTTTCCCTTAGTGA; GenBankTM
accession number AF004944), IL-1
(AAGGAGAATGTGGTGATGGTG and CAGAAGAAGAGGAGGTTGGTC; GenBankTM accession number
M37210), TNF-
(CTCAAGCCTCAAGTAACAAGC and GCAATGATCCCAAAGTAGACC;
GenBankTM accession number Z48808), and GAPDH
(TGGTATCGTGGAAGGACTCAT and GTGGGTGTCGCTGTTGAAGTC;
GenBankTM accession number X01677). PCR products were
separated on 3% agarose gels, stained with ethidium bromide, and their
nucleotide sequences verified using an Applied Biosystems 310 Genetic
Analyzer. The cDNA sequences obtained for bovine aggrecanase-1 and
aggrecanase-2 have been deposited to GenBankTM under
accession numbers AF192770 and AF192771.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
18:3
linolenate) or a saturated (16:0 palmitate) fatty acid are shown in
Table I. Exposure to the n-3
fatty acid markedly changed the overall lipid composition profile of
the chondrocyte with major changes occurring in the supplemented fatty
acid (e.g.
18:3 linolenate), with a concomitant reduction
in other polyunsaturated fatty acids. Similarly, supplementation with
16:0 palmitate markedly altered the level of this fatty acid in the
chondrocyte lipid composition profile, again at the expense of
polyunsaturated fatty acid components. Replicate cultures, with or
without prior fatty acid supplementation, were then cultured for a
further 96 h in the absence or presence of IL-1
. Proteoglycan
synthesis, as measured by [35S]sulfate incorporation, was
decreased in chondrocyte cultures treated with IL-1
compared with
controls as has been reported previously (29). However, prior addition
of fatty acids to the cultures had no effect on these changes in
proteoglycan synthesis or in cell numbers, DNA content or morphology,
nor in levels of lactate secreted into the medium (results not shown),
thus demonstrating that fatty acid supplementation was not toxic to the
chondrocytes. Furthermore, unaltered expression of mRNAs for
aggrecan and collagen type II confirmed maintenance of the chondrocyte
phenotype in the experimental cultures (results not shown).
Fatty acid analysis of chondrocyte membranes from cultures treated with
(+) or without (
) 100 µg/ml n-3 polyunsaturated or saturated fatty
acids
The effect of fatty acid supplementation on chondrocyte aggrecanase
activity was then investigated (Fig. 1).
There was no evidence for aggrecanase activity in conditioned medium
from control cultures supplemented with either n-3 (Fig.
1A, lanes 1 and 2) or saturated fatty
acids (Fig. 1B, lanes 1 and 2).
Exposure to IL-1, as expected (8), did induce aggrecanase activity in
these conditioned media (Fig. 1, A and B,
lane 3, respectively). However, addition of the
n-3 fatty acid
18:3 linolenate abolished this IL-1-induced aggrecanase activity in a dose-dependent
manner (Fig. 1A, lanes 4-6). In contrast,
supplementation with 16:0 palmitate had no effect on aggrecanase
activity (Fig. 1B, lanes 4-6). In replicate
studies, no evidence for matrix metalloproteinase-mediated aggrecan
cleavage was observed for cultures maintained in the absence or
presence of either n-3 or saturated fatty acids (results not
shown). In keeping with the observed loss of aggrecanase-mediated proteolytic activity in IL-1-treated chondrocyte conditioned medium, there was also a decrease in the levels of mRNA transcripts for aggrecanase-1 and aggrecanase-2 in response to n-3 fatty
acid supplementation (Fig. 2).
Aggrecanase-1 mRNA was detected in IL-1-treated, but not control,
cultures, whereas mRNA for aggrecanase-2 was detected both in the
presence and absence of IL-1 (Fig. 2, A and B,
lanes 1 and 2). However, addition of the
n-3 fatty acid
18:3 linolenate caused a decrease in both
aggrecanase-1 and aggrecanase-2 transcript levels (Fig. 2A,
lanes 3-5). In contrast, cultures supplemented with 16:0
palmitate expressed aggrecanase-1 and aggrecanase-2 mRNAs at all
concentrations of fatty acid tested (Fig. 2B, lanes 3-5). The addition of the vehicle for fatty acid supplementation (fatty acid-free albumin) had no effect on either aggrecanase-1 or -2 expression in the control or IL-1-treated cultures (results not shown).
Expression of GAPDH was used to normalize the amount of mRNA
present in all samples.
|
|
We next examined the effect of supplementation with n-3
fatty acids versus other fatty acids on COX-1 and COX-2
mRNA expression and on the expression of IL-1
and TNF-
mRNAs in chondrocyte cultures exposed to exogenous IL-1 (Fig.
3). Chondrocyte COX-1 mRNA was
present in all culture systems, with or without fatty acid
supplementation (Fig. 3A, lanes 1-5). However,
chondrocyte COX-2 expression was detected in IL-1-treated, but not
control, cultures (Fig. 3A, lanes 1 and
2). Significantly, COX-2 mRNA expression in IL-1-treated
cultures was decreased by n-3 fatty acid (
18:3 linolenate) supplementation (Fig. 3A, lanes
3-5). In contrast, addition of a saturated fatty acid (16:0
palmitate) had no such effect on IL-1-induced COX-2 expression (data
not shown). Examination of chondrocyte-derived cytokine expression
revealed that the mRNAs for IL-1
and TNF-
were absent in
control cultures (Fig. 3B, lane 1), but these
were detected following exposure to exogenous IL-1
(Fig.
3B, lane 2). However, expression of chondrocyte
IL-1
and TNF-
mRNAs was decreased in n-3 fatty
acid-treated cultures (Fig. 3B, lanes 3-5), but
not in cultures supplemented with saturated fatty acids (data not
shown).
|
Identical results to those shown in Figs. 1-3 were obtained when two other n-3 fatty acids found in fish oils (eicosapentaenoic acid and docosahexaenoic acid) were added to the culture systems, and no effects were observed when either an n-6 fatty acid (linoleic acid) or a monounsaturated fatty acid (oleic acid) were supplemented (data not shown). These results conclusively indicate that the observed effects on the expression of chondrocyte aggrecanases, COX-2, and autocrine cytokines are specific to supplementation with n-3 (omega-3) fatty acids.
Collectively, these data provide informative novel information on the
biological and molecular mechanisms whereby dietary fish oil
supplementation can reduce inflammatory and degradative aspects of
articular joint disease and thus modulate disease progression. The
balance of dietary n-3/n-6 polyunsaturated fatty
acids is well known to affect inflammatory responses (30).
Polyunsaturated fatty acids of the n-6 series, such as
linoleic acid, are intimately involved in the production of
inflammatory eicosanoids (31), and n-3 polyunsaturated fatty
acids can interfere with this process at, for example, the desaturation
steps or by producing alternative eicosanoids with different activities
(32). On the other hand, accumulating evidence suggests that
n-3 fatty acids can regulate gene expression via activation
of transcription factors such as peroxisome proliferator-activated
receptor-
or by affecting expression levels of sterol regulatory
element-binding proteins (33). Whereas such mechanisms remain to be
investigated in chondrocytes, our current findings demonstrate that
n-3 fatty acid supplementation can specifically affect
molecular mechanisms that regulate the expression of catabolic factors
involved in articular cartilage degradation and thus further advocate a
beneficial role for dietary fish oils in alleviation of several of the
physiological parameters that cause and propogate arthritic disease.
| |
FOOTNOTES |
|---|
* This work was funded by the Arthritis Research Campaign, United Kingdom.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF192770 and AF192771.
Arthritis Research Campaign Postdoctoral Research Fellow.
§ Arthritis Research Campaign Postdoctoral Research Fellow.
¶ To whom correspondence should be addressed: Connective Tissue Biology Laboratories, Cardiff School of Biosciences, Cardiff University, Museum Ave., Biomedical Sciences Bldg., Cardiff CF10 3US, Wales, UK. E-mail: caterson@Cardiff.ac.uk.
2 Approved nomenclature (trivial names) for fatty acids is as recommended by the IUPAC-IUB.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: COX, cyclooxygenase; IL, interleukin; TNF, tumor necrosis factor; RT-PCR, reverse transcription-polymerase chain reaction.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Vane, J. R., Bakhle, Y. S., and Botting, R. M. (1998) Annu. Rev. Pharmacol. Toxicol. 38, 97-120[CrossRef][Medline] [Order article via Infotrieve] |
| 2. |
Smith, W. L.,
Garavito, R. M.,
and Dewitt, D. L.
(1996)
J. Biol. Chem.
271,
33157-33160 |
| 3. | Volker, D., and Garg, M. (1996) J. Clin. Biochem. Nutr. 20, 83-87 |
| 4. | Kremer, J. M. (1996) Lipids 31, S243 |
| 5. | Ariza-Ariza, R., Mestanza-Peralta, M., and Cardiel, M. H. (1998) Semin. Arthritis Rheum. 27, 366-370[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Lee, T. H., Hoover, R. L., Williams, J. D., Sperling, R. I., Ravalese, J., Spur, B. W., Robinson, D. R., Corey, E. J., Lewis, R. A., and Austen, K. F. (1985) N. Engl. J. Med. 312, 1217-1224[Abstract] |
| 7. | Sperling, R. I., Benincaso, A. I., Knoell, C. T., Larkin, J. K., Austen, K. F., and Robinson, D. R. (1993) J. Clin. Invest. 91, 651-660 |
| 8. | Sandy, J. D., Flannery, C. R., Neame, P. J., and Lohmander, L. S. (1992) J. Clin. Invest. 89, 1512-1516 |
| 9. |
Hughes, C. E.,
Little, C. B.,
Büttner, F. H.,
Bartnik, E.,
and Caterson, B.
(1998)
J. Biol. Chem.
273,
30576-30582 |
| 10. |
Arner, E. C.,
Pratta, M. A.,
Trzaskos, J. M.,
Decicco, C. P.,
and Tortorella, M. D.
(1999)
J. Biol. Chem.
274,
6594-6601 |
| 11. | Little, C. B., Flannery, C. R., Hughes, C. E., Mort, J. S., Roughley, P. J., Dent, C., and Caterson, B. (1999) Biochem. J. 344, 61-68 |
| 12. |
Tortorella, M. D.,
Burn, T. C.,
Pratta, M. A.,
Abbaszade, I.,
Hollis, J. M.,
Liu, R.,
Rosenfeld, S. A.,
Copeland, R. A.,
Decicco, C. P.,
Wynn, R.,
Rockwell, A.,
Yang, F.,
Duke, J. L.,
Solomon, K.,
George, H.,
Bruckner, R.,
Nagase, H.,
Itoh, Y.,
Ellis, D. M.,
Ross, H.,
Wiswall, B. H.,
Murphy, K.,
Hillman, M. C., Jr.,
Hollis, G. F.,
Newton, R. C.,
Magolda, R. L.,
Trzaskos, J. M.,
and Arner, E. C.
(1999)
Science
284,
1664-1666 |
| 13. |
Abbaszade, I.,
Liu, R.-Q.,
Yang, F.,
Rosenfeld, S. A.,
Ross, O. H.,
Link, J. R.,
Ellis, D. M.,
Tortorella, M. D.,
Pratta, M. A.,
Hollis, J. M.,
Wynn, R.,
Duke, J. L.,
George, H. J.,
Hillman, M. C., Jr.,
Murphy, K.,
Wiswall, B. H.,
Copeland, R. A.,
Decicco, C. P.,
Bruckner, R.,
Nagase, H.,
Itoh, Y.,
Newton, R. C.,
Magolda, R. L.,
Trzaskos, J. M.,
Hollis, G. F.,
Arner, E. C.,
and Burn, T. C.
(1999)
J. Biol. Chem.
274,
23443-23450 |
| 14. |
Sandy, J. D.,
Neame, P. J.,
Boynton, R. E.,
and Flannery, C. R.
(1991)
J. Biol. Chem.
266,
8683-8685 |
| 15. | Aydelotte, M. B., Raiss, R. X., Caterson, B., and Kuettner, K. E. (1992) Connect. Tissue Res. 28, 143-159[Medline] [Order article via Infotrieve] |
| 16. | Ilic, M. Z., Handley, C. J., Robinson, H. C., and Mok, M. T. (1992) Arch. Biochem. Biophys. 294, 115-122[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Loulakis, P., Shrikhande, A., Davis, G., and Maniglia, C. A. (1992) Biochem. J. 284, 589-593 |
| 18. | Arner, E. C., Hughes, C. E., Decicco, C. P., Caterson, B., and Tortorella, M. D. (1998) Osteoarthritis Cartilage 6, 214-228[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Smith, W. L., and Dewitt, D. L. (1996) Adv. Immunol. 62, 167-170[Medline] [Order article via Infotrieve] |
| 20. |
Anderson, G. D.,
Hauser, S. D.,
McGarity, K. L.,
Bremer, M. E.,
Isakson, P. C.,
and Gregory, S. A.
(1996)
J. Clin. Invest.
97,
2672-2679 |
| 21. | Crofford, L. J., Wilder, R. L., Ristimaki, A. P., Sano, H., Remmers, E. F., Epps, H. R., and Hla, T. (1994) J. Clin. Invest. 93, 1095-1101 |
| 22. | Blanco, F. J., Guitian, R., Moreno, J., de Toro, F. J., and Galdo, F. (1999) J. Rheumatol. 26, 1366-1373[Medline] [Order article via Infotrieve] |
| 23. | Sicard, B., and Lagarde, M. (1985) Thromb. Haemostasis 53, 264-267[Medline] [Order article via Infotrieve] |
| 24. |
Garbus, J.,
DeLuca, H. F.,
Loomans, M. E.,
and Strong, F. M.
(1963)
J. Biol. Chem.
238,
59-63 |
| 25. | Kim, Y.-J., Sah, R. L. Y., Doong, J.-Y. H., and Grodzinsky, A. J. (1988) Anal. Biochem. 174, 168-176[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Farndale, R. W., Buttle, D. J, and Barret, A. J. (1986) Biochim. Biophys. Acta 883, 173-177[Medline] [Order article via Infotrieve] |
| 27. | Flannery, C. R., Little, C. B., Caterson, B., and Hughes, C. E. (1999) Matrix Biol. 18, 225-237[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Bang, H. O., Dyerberg, J., and Nielsen, A. B. (1971) Lancet 1, 1143-1146[Medline] [Order article via Infotrieve] |
| 29. | Tyler, J. A. (1985) Biochem. J. 227, 869-878[Medline] [Order article via Infotrieve] |
| 30. | Okuyama, H., Kobayashi, T., and Watanabe, S. (1996) Prog. Lipid Res. 35, 409-457[CrossRef][Medline] [Order article via Infotrieve] |
| 31. | Griswold, D. E., and Adams, J. L. (1996) Med. Res. Rev. 16, 181-206[CrossRef][Medline] [Order article via Infotrieve] |
| 32. | Gurr, M. I., and Harwood, J. L. (1991) Lipid Biochemistry: An Introduction , 4th Ed. , Chapman and Hall, London |
| 33. |
Kim, H.-J.,
Takahashi, M.,
and Ezaki, O.
(1999)
J. Biol. Chem.
274,
25892-25898 |
This article has been cited by other articles:
![]() |
A. Gonzalez-Periz, A. Planaguma, K. Gronert, R. Miquel, M. Lopez-Parra, E. Titos, R. Horrillo, N. Ferre, R. Deulofeu, V. Arroyo, et al. Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA FASEB J, December 1, 2006; 20(14): 2537 - 2539. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Benatti, G. Peluso, R. Nicolai, and M. Calvani Polyunsaturated Fatty Acids: Biochemical, Nutritional and Epigenetic Properties J. Am. Coll. Nutr., August 1, 2004; 23(4): 281 - 302. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kashiwagi, J. J. Enghild, C. Gendron, C. Hughes, B. Caterson, Y. Itoh, and H. Nagase Altered Proteolytic Activities of ADAMTS-4 Expressed by C-terminal Processing J. Biol. Chem., March 12, 2004; 279(11): 10109 - 10119. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Worley, M. D. Baugh, D. A. Hughes, D. R. Edwards, A. Hogan, M. J. Sampson, and J. Gavrilovic Metalloproteinase Expression in PMA-stimulated THP-1 Cells: EFFECTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-{gamma} (PPAR{gamma}) AGONISTS AND 9-CIS-RETINOIC ACID J. Biol. Chem., December 19, 2003; 278(51): 51340 - 51346. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Abulencia, R. Gaspard, Z. R. Healy, W. A. Gaarde, J. Quackenbush, and K. Konstantopoulos Shear-induced Cyclooxygenase-2 via a JNK2/c-Jun-dependent Pathway Regulates Prostaglandin Receptor Expression in Chondrocytic Cells J. Biol. Chem., August 1, 2003; 278(31): 28388 - 28394. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. D. Martin, P. E. Lonergan, B. Boland, M. P. Fogarty, M. Brady, D. F. Horrobin, V. A. Campbell, and M. A. Lynch Apoptotic Changes in the Aged Brain Are Triggered by Interleukin-1beta -induced Activation of p38 and Reversed by Treatment with Eicosapentaenoic Acid J. Biol. Chem., September 6, 2002; 277(37): 34239 - 34246. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Malfait, R.-Q. Liu, K. Ijiri, S. Komiya, and M. D. Tortorella Inhibition of ADAM-TS4 and ADAM-TS5 Prevents Aggrecan Degradation in Osteoarthritic Cartilage J. Biol. Chem., June 14, 2002; 277(25): 22201 - 22208. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Wallace Nutritional and Botanical Modulation of the Inflammatory Cascade--Eicosanoids, Cyclooxygenases, and Lipoxygenases-- As an Adjunct in Cancer Therapy Integr Cancer Ther, March 1, 2002; 1(1): 7 - 37. [Abstract] [PDF] |
||||
![]() |
B. A. Watkins, Y. Li, and M. F. Seifert Nutraceutical Fatty Acids as Biochemical and Molecular Modulators of Skeletal Biology J. Am. Coll. Nutr., October 1, 2001; 20(90005): 410S - 416. [Abstract] [Full Text] |
||||
![]() |
B. A. Watkins, Y. Li, H. E. Lippman, and M. F. Seifert Omega-3 Polyunsaturated Fatty Acids and Skeletal Health Experimental Biology and Medicine, June 1, 2001; 226(6): 485 - 497. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Berton, V. Rigot, E. Huet, M. Decarme, Y. Eeckhout, L. Patthy, G. Godeau, W. Hornebeck, G. Bellon, and H. Emonard Involvement of Fibronectin Type II Repeats in the Efficient Inhibition of Gelatinases A and B by Long-chain Unsaturated Fatty Acids J. Biol. Chem., June 1, 2001; 276(23): 20458 - 20465. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |